Rotate exposure from NVIDIA (NVDA) into Taiwan Semiconductor Manufacturing Company (TSM) to capitalize on the tech sector's structural shift toward custom ASICs. Within mega-cap tech, prioritize the stability and strong execution of Microsoft (MSFT) and Apple (AAPL) over margin-pressured peers like Amazon (AMZN) and Meta Platforms (META). Capitalize on recent clinical selloffs by buying undervalued core assets in Ultragenyx Pharmaceutical (RARE), while treating Spruce Biosciences (SPRB) as a patient, long-term opportunity toward a $500 price target. Short or avoid Capricor Therapeutics (CAPR) and Amylyx Pharmaceuticals (AMLX) ahead of expected product-launch headwinds and questionable trial data. Protect overall capital by applying disciplined Kelly Criterion position sizing and dollar-neutral sector hedging instead of taking oversized, unhedged bets.

NVIDIA (NVDA)

• Expressed a growing bearish outlook on the company due to shifts in artificial intelligence hardware architecture.
  • Argued that NVIDIA's proprietary CUDA software moat is losing its competitive edge as the industry standardizes machine code instructions and moves toward inference-focused models.
  • Stated that major AI companies like OpenAI are increasingly moving toward custom silicon and Application-Specific Integrated Circuits (ASICs) rather than relying exclusively on general-purpose GPUs.
  • Highlighted rising risks regarding customer concentration in the AI sector, noting that AI labs generate the majority of their revenue from their top 1% of customers.

Takeaways

• Consider the risk of slowing growth and margin pressure for NVDA as large tech companies transition toward in-house, custom silicon alternatives.

Custom Silicon & Semiconductor Manufacturing (TSM)

• Bullish on the custom chip and ASIC sector over general AI research labs, stating that AI labs are becoming saturated while semiconductor infrastructure remains critical.
  • Noted that Taiwan Semiconductor Manufacturing Company (TSM) stands to benefit directly as the primary foundry manufacturing these emerging ASICs and custom silicon designs.

Takeaways

• Focus on the semiconductor manufacturing layer (such as TSM) rather than software-layer AI labs to capture the secular shift toward custom silicon.

Ultragenyx Pharmaceutical (RARE)

• Addressed the stock's pullback following a failed Phase 3 clinical trial for its Angelman syndrome candidate.
  • Stated a leaning positive/bullish outlook on the company despite the trial headline.
  • Explained that the Angelman trial had minimal value in fundamental financial models, meaning the remaining core business assets remain undervalued.

Takeaways

• Look for potential buying opportunities in RARE following clinical trial-related selloffs if the underlying pipeline and commercial assets remain fundamentally solid.

Spruce Biosciences (SPRB)

• Reaffirmed a long-term bullish stance on the company.
  • Acknowledged that reaching a $500 price level by the end of the year appears unlikely, but maintained that the company fundamentally has the potential to reach $500 over a longer time horizon.

Takeaways

• View SPRB as a long-term, high-volatility clinical biotech play rather than expecting short-term price appreciation.

Big Tech: Microsoft (MSFT), Apple (AAPL), Meta (META), Amazon (AMZN)

• Provided comparative analysis across the "Magnificent Seven" mega-cap technology companies:
  • Microsoft (MSFT): Highlighted as one of the best-managed and most operationally efficient large-scale enterprises in corporate history.
  • Apple (AAPL): Viewed as a exceptionally safe franchise with a reliable, simple business model.
  • Meta Platforms (META): Commended for strong management and asset utilization, but noted vulnerability to fast-moving social media competitors such as ByteDance (TikTok).
  • Amazon (AMZN): Described as elevated risk due to low-margin e-commerce operations and increasing commoditization in cloud computing (AWS), where renting server capacity faces severe price and infrastructure competition.

Takeaways

• Prioritize MSFT and AAPL for high-quality balance sheets and defensive stability, while exercising caution with AMZN regarding cloud infrastructure margins and META regarding audience retention.

Biotech Shorts: Capricor Therapeutics (CAPR) & Amylyx Pharmaceuticals (AMLX)

• Outlined short positions across specific binary-event biotech equities:
  • Capricor Therapeutics (CAPR): Maintained an aggressive short bias, citing severe distrust in the company's scientific claims and reported clinical trial statistics.
  • Amylyx Pharmaceuticals (AMLX): Disclosed a short position based on expectations that the stock will experience selling pressure and fade as it approaches its product launch.

Takeaways

• Avoid long exposure to CAPR and AMLX due to underlying skepticism around clinical trial validity and post-launch commercial performance.

Portfolio Strategy & The Kelly Criterion

• Emphasized disciplined position sizing and risk management over chasing rapid, short-term gains.
  • Highlighted the Kelly Criterion as a mathematical model for optimal capital allocation, warning that even a trader with a 55% win rate will face total portfolio ruin if positions are consistently oversized.
  • Warned against the Martingale strategy (doubling down on losing trades), demonstrating that it inevitably leads to catastrophic drawdown.
  • Recommended dollar-neutral hedging (matching equal numbers of long and short positions within the same sector) to isolate company-specific edge rather than taking unhedged directional market bets.

Takeaways

• Prevent portfolio blowups by reducing individual bet sizes, chronically under-betting rather than over-betting, and using hedging strategies to manage broader market risk.